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Graves’diseaseisathyroid-speciﬁcautoimmunedisorderinwhichthebodymakes antibodiestothethyroid-stimulatinghormone
receptor leading to hyperthyroidism. Therapeutic options for the treatment of Graves’ disease include medication, radioactive
iodine ablation, and surgery. Radioactive iodine is absolutely contraindicated in pregnancy as exposure to I-131 to the fetal thyroid
can result in fetal hypothyroidism and cretinism. Here we describe a case of a female patient with recurrent Graves’ disease, who
inadvertently received I-131 therapy when shewas estimated tobe eight days pregnant. This was despite the obtaining of a negative
history of pregnancy and a negative urine pregnancy test less than 24 hours prior to ablation. At birth, the infant was found to
have neonatal Graves’ disease. The neonatal Graves’ disease resolved spontaneously. It was suspected that the fetal thyroid did not
trap any I-131 as it does not concentrate iodine until 10 weeks of gestation.
1.Introduction
Radioactive iodine thyroid ablation has been shown to be
an inexpensive, safe, and eﬀective treatment for hyperthy-
roidism [1]. It is the most commonly used method for
treating adult patients with Graves’ disease [2]. It is very
important not to treat a woman who is pregnant or nursing.
Special precautions must be used in women of child-bearing
age because of the possible detrimental side eﬀects of fetal
exposure [3].
The American College of Radiology (ACR) practice
guideline for the performance of therapy with unsealed
radiopharmaceutical sources states that pregnancy should
be ruled out using one of the following four criteria: (1) a
negative hCG test obtained within 72 hours prior to admin-
istrationoftheradiopharmaceutical,(2)documentedhistory
of hysterectomy, (3) a postmenopausal state with absence of
menstrual bleeding for two years, and (4) premenarche in a
child age of 10 years or younger [4]. The Society of Nuclear
Medicine (SNM) procedure guideline for therapy of thyroid
disease with I-131 states that females of child-bearing age
should routinely be tested for pregnancy within 72 hours or
lessbeforeI-131treatment.Whenthepatient’shistoryclearly
indicates that pregnancy is impossible, the treating physician
may omit the pregnancy test [5].
2.CaseReport
TJ (not the patient’s initials) is an adult female diagnosed
with Graves’ disease, which was treated with I-131 therapy
in December 2004. She had been doing well until June
2006 when she presented to the pediatric endocrinology
clinic with reoccurrence of her disease. Her thyroid function
tests showed TSH < 0.03 (normal 0.32–5.0munit/mL), free
T4 2.80 (normal 0.71–1.85ng/dL), and T4 19.1 (normal
5.0–12.0mcg/dL). Unfortunately, her menstrual history was
not documented during this clinic visit. TJ was scheduled2 International Journal of Pediatric Endocrinology
for a radioactive iodine uptake and scan with subsequent
ablation with I-131. A qualitative urine pregnancy test was
performed 24 hours prior to ablation and was negative.
A radioiodine uptake and scan revealed a 24-hour uptake
of 100% (normal 10%–30%). Informed consent for I-131
therapy was obtained. TJ veriﬁed that she was not pregnant
and was given an activity of 19.8mCi of I-131. This dosage
was used due to the patient’s prior failed therapy.
Approximately four months later, after slipping and
falling at work, TJ presented to her physician with a com-
plaint of low back pain. Magnetic resonance imaging (MRI)
of her lumbar spine revealed an intrauterine pregnancy.
TJ again denied any possibility of being pregnant prior
to the MRI. A subsequent ultrasound showed the fetus at
approximately 17 4/7-week gestation. It was estimated that
the fetus was eight to ten days old at the time of I-131
treatment.
TJ delivered a full-term male infant. Neonatal thyroid
function tests revealed suppressed TSH (<0.02, normal 0.32–
5.0munit/mL), elevated T4 (24.4, normal 5.0–12.0mcg/dL),
and free T4 (4.54, normal 0.58–1.64ng/dL). In addition, the
infanthadanelevatedthyroidreceptorantibody(TRab)titer
of 82% (negative <10%, intermediate 10%–15%, positive
>15%). Based on the laboratory evaluation, it was suspected
that the infant had neonatal hyperthyroidism secondary
to maternal antibodies. Because he was asymptomatic, a
decision was made not to treat but to monitor him closely.
Over the next six months, the infant grew, gained weight,
and reached developmental milestones appropriately. His
thyroid function tests normalized with TSH 0.73munit/mL,
T4 10.3mcg/dL, free T4 1.11ng/dL, and TRab <15%.
3. Discussion
Thyroid embryogenesis is largely completed by 10–12-week
gestation. At 10-week gestation, the thyroid gland is able
to trap and concentrate iodine and synthesize thyroid hor-
mones thyroxine and triiodothyronine [6]. Iodine, including
radioactive isotopes, is readily transferred across the placenta
[7]. After 10-week gestation, signiﬁcant exposure to the fetal
thyroid can occur from therapeutic doses to the mother,
resulting in hypothyroidism and cretinism [8]. There have
been no reports of birth defects or childhood malignancy
in children born to the mothers who received radioactive
iodine for Graves’ disease before the 10th week of pregnancy
[9]. We believe the infant’s thyroid gland was not aﬀected by
the I-131 therapy because he was exposed prior to 10-week
gestation.
Quantifying the exact absorbed dose by the embryo in
t h i sc a s ei sd i ﬃcult and depends on many variables. Using
the methodology provided by Russell et al., a rough estimate
of the dose that the embryo received can be calculated
[10]. This calculation likely overstates the actual absorbed
dose, as the model assumes that I-131 crosses the placenta.
In this case, due to the placenta being in the early stages
of development during the second week of gestation, the
amountofI-131thatcrossedwouldbelimited.Itisestimated
that the embryo absorbed dose with I-131 treatment in early
pregnancy is 0.072mGy/MBq [10]. Our patient received
a dose of 19.8mCi (732.6MBq), which corresponds to an
absorbed dose of approximately 5.3rads after converting
from Gy to rads. Again, this likely represents a greater dose
than the embryo actually received.
Radiation-induced eﬀe c t sc a nb eb r o k e nd o w ni n t o
deterministic eﬀects and stochastic eﬀects. Deterministic
eﬀects are those that are known to occur at a given radiation
threshold. For example, if a patient were to receive an acute
dose of 2Gy to the lens of the eye, the patient will develop
a cataract. Stochastic eﬀects are those that can theoretically
occur at any radiation dose. For example, any radiation
dose could potentially induce a cancer in the future. The
p r o b a b i l i t yo fas t o c h a s t i ce ﬀect increases as dose increases,
but there is no radiation threshold dose below which one can
say a stochastic eﬀect will not occur. Therefore, stochastic
eﬀects can theoretically occur with any radiation dose. The
only known deterministic eﬀect of radiation at an absorbed
dose of less than 10rads is possible spontaneous abortion
at 1–14 days postconception. Based on the data above, this
dose level (10rads) was not reached in this patient. On the
other hand, stochastic eﬀects are theoretically possible at any
level of radiation dose [11]. Thus, the radiation dose to any
developingembryoshouldbeminimized,anditisreasonable
to ascertain an accurate pregnancy test prior to the use of I-
131 therapy.
Studies have demonstrated that the risk of congenital
eﬀects have been negligible at doses of 5rads or less when
compared to other risks of pregnancy. In addition, the risk
of malformation only signiﬁcantly increases at doses above
15rads. Mental retardation has been shown to occur in
the oﬀspring of pregnant mothers; however, it is at doses
greater than 20rads and generally after the eighth week of
gestation [12]. A screening study of thyroid cancer among
individuals exposed to in utero I-131 from the Chernobyl
fallout, however, did demonstrate an increased risk of
thyroid carcinoma approximately 20 years after the accident
[13]. Thus, our estimation that the infant was exposed to
approximately 5rads supports that no deterministic eﬀects
should have occurred, but one cannot exclude the future
potential for stochastic eﬀects.
As previously stated, the ACR practice guideline for the
performance of therapy with unsealed radiopharmaceutical
sources states that pregnancy should be ruled out using
one of the following four criteria: (1) a negative hCG test
obtained within 72 hours prior to administration of the
radiopharmaceutical, (2) documented history of hysterec-
tomy, (3) a postmenopausal state with absence of menstrual
bleeding for two years, and (4) premenarche in a child age 10
or younger [4]. The SNM procedure guideline for therapy of
thyroiddiseasewithI-131statesthatfemalesofchild-bearing
age should routinely be tested for pregnancy within 72 hours
or less before I-131 treatment. When the patient’s history
clearly indicates that pregnancy is impossible, the treating
physician may omit the pregnancy test [5]. Neither of the
aboveguidelinesspeciﬁeswhetherthepregnancytestsshould
be quantitative or qualitative.
Typically, serum pregnancy tests are more sensitive
than standard urine pregnancy tests because the serum
concentration of hCG is signiﬁcantly higher than its urineInternational Journal of Pediatric Endocrinology 3
concentration [14]. Detection of hCG in maternal serum is
evidentonlyafterimplantationandvascularcommunication
has been established with the decidua by the syncytiotro-
phoblast, which occurs 8–10 days following conception.
Serum hCG can be detected in about 5% of patients eight
days after conception and about 98% of patients by 11 days
postconception [15]. In contrast, urine pregnancy tests will
be positive 15–17 days after conception in 98% of patients
[14, 16]. Alternatively, many experts advocate that use of
the Ten Day Rule. This rule suggests that radioactive iodine
therapy only be administered during the 10 days after the
onset of the menstrual period [17]. However, this protocol
may not be eﬀective if the patient has irregular menstrual
cycles.
One possible suggestion is to incorporate the Ten Day
Rule protocol into the current guidelines for patients who
haveregular28-daymenstrualcycles.Forpatientswithirreg-
ular cycles or who require immediate ablation, quantitative
serum hCG pregnancy tests on the day of the treatment
shouldbeconsidered.BecauseserumhCGisdetectedin98%
of pregnant patients by day 11, recommending the patients
to abstain from sexual activity for at least two weeks prior
to I-131 therapy may be suggested. This abstinence would
cover the gap from the time of conception to the time the
serum hCG test becoming positive. However, the physician
would have to rely on the patient for providing an accurate
menstrual cycle and sexual history.
4. Conclusion
It is imperative to rule out pregnancy prior to the admin-
istration of radioactive iodine therapy due to the potential
detrimental side eﬀects of fetal exposure. The dose of I-
131 in this particular case would be unlikely to result
in any deterministic events. However, under the premise
that any unnecessary exposure to radiation is important
in preventing any potential stochastic events, an accurate
pregnancy screening protocol may be warranted in pre-
venting inadvertent I-131 treatment in early pregnancies
of women with Graves’ disease. The current ACR and
SNM guidelines only mandate a hCG test being obtained
within 72 hours prior to the treatment. This approach
may miss a small number of pregnancies as a serum
or urine pregnancy test does not become positive until
implantation occurs, which happens 8–10 days postconcep-
tion. Though we recommend re-evaluating the ACR and
SNM guidelines for future clariﬁcations, it is possible that
despite combining the patient’s history, the Ten Day Rule
and the hCG screening, an unsuspected pregnancy may be
missed.
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